HYUNDAI PHARMACEUTICAL CO., LTD
004310 | KO
Overview
Corporate Details
- ISIN(s):
- KR7004310009
- LEI:
- Country:
- South Korea
- Address:
- 충청남도 천안시 동남구 풍세면 잔다리길 55, 천안시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 9.0 KB | ||
| 2025-07-14 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 14.8 KB | ||
| 2025-07-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.05)
|
Korean | 876.8 KB | ||
| 2025-04-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 10.4 KB | ||
| 2025-04-28 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 8.5 KB | ||
| 2025-04-14 00:00 |
Quarterly Report
분기보고서 (2025.02)
|
Korean | 827.4 KB | ||
| 2025-02-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 23.9 KB | ||
| 2025-02-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.8 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 11.9 KB | ||
| 2025-02-19 00:00 |
Audit Report / Information
[첨부추가]사업보고서 (2024.11)
|
Korean | 524.8 KB | ||
| 2025-02-12 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 15.8 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.9 KB | ||
| 2025-02-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 109.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 8.6 KB | ||
| 2025-02-12 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 6.1 KB |
Automate Your Workflow. Get a real-time feed of all HYUNDAI PHARMACEUTICAL CO., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for HYUNDAI PHARMACEUTICAL CO., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for HYUNDAI PHARMACEUTICAL CO., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
United States of America
RCUS
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
United States of America
ARQT
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
United States of America
ARDX
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
United Kingdom
AREC
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Netherlands
1AE
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
United States of America
ARMP
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
Sweden
AROC
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP
United States of America
AVBP
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
United States of America
ARWR
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY
United States of America
SPRY